我们是否使用ezetimibe尽可能多?
Antonis A Manolis1, Theodora A Manolis2, Dimitri P Mikhailidis3
1Cardiology Department, Evagelismos Hospital, Athens, Greece.
Biomarker insights
|June 3, 2024
概括
埃泽蒂米布是一种有效且负担得起的降脂疗法,通常与他类药物一起使用,以达到低密度脂蛋白胆固醇 (LDL-C) 的目标. 它改善了心血管结果,是对他类药物不耐受患者的好替代品.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 预防医学 预防医学
背景情况:
- 许多患有动脉样硬化心血管疾病 (CVD) 的患者在单独使用他类药物治疗时无法达到目标低密度脂蛋白胆固醇 (LDL-C) 水平.
- 斯坦丁相关的不良影响限制了它们的广泛使用和心血管疾病的最佳管理.
- 尽管对有效降低心血管疾病风险的需求尚未得到满足,但非他类降脂疗法仍未得到充分利用.
研究的目的:
- 提供埃泽蒂米布对降脂,心血管 (CV) 事件减少和结果改善的影响的全面审查.
- 评估以泽提米布作为单一疗法或与他类药物结合用于治疗失脂症和降低心血管疾病风险.
- 评估ezetimibe作为他类药物不耐受患者的替代治疗的作用.
主要方法:
- 对ezetimibe的临床试验数据和结果研究的审查.
- 分析埃泽提米布在单一治疗和与他类药物联合治疗中的疗效.
- 与其他降脂剂相比,对ezetimibe的安全性和耐受性概况的评估.
主要成果:
- 作为口服单一疗法或与他类药物结合,以泽是实现LDL-C目标的有效和负担得起的选择.
- 结合治疗以埃泽提米布和他类药物增强了降脂效应 (大约. 20%) 并允许降低他类药物的剂量,减少副作用.
- 埃泽提米布在降低心血管疾病风险和事件方面表现出有效性,并得到了心血管结果数据的支持.
结论:
- 埃泽蒂米布是一种方便和有效的第一线补充疗法,用于达成LDL-C目标.
- 它提供了卓越的安全性和耐受性,增强降脂效果,并可能减轻与他类药物相关的副作用.
- 对于无法耐受他类药物的患者来说,ezetimibe 是一种有价值的替代治疗选择,有助于改善心血管疾病管理.
关键词:
这样一来,你可能会有更多的兴趣.心血管疾病心血管疾病胆固醇 胆固醇 胆固醇 是一种冠状动脉疾病是一种冠状动脉疾病.脱脂血症是什么情况脂质 脂质 脂质 是一种蛋白质脂质蛋白质 (lipoprotein) 是一种脂肪蛋白质.心肌梗塞的心脏病发作更多相关视频
06:00Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
Published on: March 17, 2023
462
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.0K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
647
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
647
01:20Antiepileptic Drugs: Potassium Channel Activators
171
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
171
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:23Antidepressant Drugs: MAOIs and Other Agents
220
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
220
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
01:17Antiepileptic Drugs: Calcium Channel Blockers
371
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
371